NDC 0591-3851 Vigabatrin

Vigabatrin

NDC Product Code 0591-3851

NDC Code: 0591-3851

Proprietary Name: Vigabatrin Additional informationCallout TooltipWhat is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Vigabatrin Additional informationCallout TooltipWhat is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.


Product Characteristics
Color(s):
WHITE (C48325 - TO OFF-WHITE)
Shape: OVAL (C48345)
Size(s):
18 MM
Imprint(s):
A314
Score: 2

Code Structure
  • 0591 - Actavis Pharma, Inc.
    • 0591-3851 - Vigabatrin

NDC 0591-3851-01

Package Description: 100 TABLET, FILM COATED in 1 BOTTLE

NDC Product Information

Vigabatrin with NDC 0591-3851 is a a human prescription drug product labeled by Actavis Pharma, Inc.. The generic name of Vigabatrin is vigabatrin. The product's dosage form is tablet, film coated and is administered via oral form.

Labeler Name: Actavis Pharma, Inc.

Dosage Form: Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.

Product Type: Human Prescription Drug Additional informationCallout TooltipWhat kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.


Vigabatrin Active Ingredient(s)

Additional informationCallout TooltipWhat is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • VIGABATRIN 500 mg/1

Inactive Ingredient(s)

Additional informationCallout TooltipAbout the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)
  • MAGNESIUM STEARATE (UNII: 70097M6I30)
  • CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
  • POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
  • POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B)
  • POLYSORBATE 80 (UNII: 6OZP39ZG8H)
  • POVIDONE (UNII: FZ989GH94E)
  • SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
  • TITANIUM DIOXIDE (UNII: 15FIX9V2JP)

Administration Route(s)

Additional informationCallout TooltipWhat are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

Additional informationCallout TooltipWhat is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Anti-epileptic Agent - [EPC] (Established Pharmacologic Class)

Product Labeler Information

Additional informationCallout TooltipWhat is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Actavis Pharma, Inc.
Labeler Code: 0591
FDA Application Number: ANDA209822 Additional informationCallout TooltipWhat is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. Additional informationCallout TooltipWhat is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 02-06-2019 Additional informationCallout TooltipWhat is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 Additional informationCallout TooltipWhat is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N Additional informationCallout TooltipWhat is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Vigabatrin Product Label Images

Vigabatrin Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Warning: Permanent Vision Loss

  • Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, vigabatrin also can damage the central retina and may decrease visual acuity [see Warnings and Precautions (5.1)].The onset of vision loss from vigabatrin is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.Symptoms of vision loss from vigabatrin are unlikely to be recognized by patients or caregivers before vision loss is severe.Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function.The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. Vision assessment is recommended at baseline (no later than 4 weeks after starting vigabatrin), at least every 3 months during therapy, and about 3 to 6 months after the discontinuation of therapy.Once detected, vision loss due to vigabatrin is not reversible. It is expected that, even with frequent monitoring, some patients will develop severe vision loss.Consider drug discontinuation, balancing benefit and risk, if vision loss is documented.Risk of new or worsening vision loss continues as long as vigabatrin is used. It is possible that vision loss can worsen despite discontinuation of vigabatrin.Because of the risk of vision loss, vigabatrin should be withdrawn from patients with refractory complex partial seizures who fail to show substantial clinical benefit within 3 months of initiation and within 2 to 4 weeks of initiation for patients with infantile spasms, or sooner if treatment failure becomes obvious. Patient response to and continued need for vigabatrin should be periodically reassessed.Vigabatrin should not be used in patients with, or at high risk of, other types of irreversible vision loss unless the benefits of treatment clearly outweigh the risks.Vigabatrin should not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks.Use the lowest dosage and shortest exposure to vigabatrin consistent with clinical objectives [see Dosage and Administration (2.1)]. Because of the risk of permanent vision loss, vigabatrin is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Vigabatrin REMS Program [see Warnings and Precautions (5.2)]. Further information is available at www.vigabatrinREMS.com or 1-866-244-8175.

1.1 Refractory Complex Partial Seizures (Cps)

Vigabatrin tablets are indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [see Warnings and Precautions (5.1)]. Vigabatrin tablets are not indicated as a first line agent for complex partial seizures.

2.1 Important Dosing And Administration Instructions

DosingUse the lowest dosage and shortest exposure to vigabatrin tablets consistent with clinical objectives [see Warnings and Precautions (5.1)].The vigabatrin tablet dosing regimen depends on the age group and weight [see Dosage and Administration (2.2]. Patients with impaired renal function require dose adjustment [see Dosage and Administration (2.4)].Vigabatrin tablets and powder for oral solution are bioequivalent. Either tablet or powder can be used for CPS. Monitoring of vigabatrin plasma concentrations to optimize therapy is not helpful. AdministrationVigabatrin tablets are given orally with or without food.If a decision is made to discontinue vigabatrin tablets, the dose should be gradually reduced [see Dosage and Administration (2.2) and Warnings and Precautions (5.6)].

2.2 Refractory Complex Partial Seizures

Adults (Patients 17 Years of Age and Older)Treatment should be initiated at 1,000 mg/day (500 mg twice daily). Total daily dose may be increased in 500 mg increments at weekly intervals, depending on response. The recommended dose of vigabatrin tablets in adults is 3,000 mg/day (1,500 mg twice daily). A 6,000 mg/day dose has not been shown to confer additional benefit compared to the 3,000 mg/day dose and is associated with an increased incidence of adverse events.In controlled clinical studies in adults with complex partial seizures, vigabatrin was tapered by decreasing the daily dose 1,000 mg/day on a weekly basis until discontinued [see Warnings and Precautions (5.6)].Pediatric (Patients 10 to 16 Years of Age)Treatment is based on body weight as shown in Table 1. Treatment should be initiated at a total daily dose of 500 mg/day (250 mg twice daily) and may be increased weekly in 500 mg/day increments to a total maintenance dose of 2,000 mg/day (1,000 mg twice daily). Patients weighing more than 60 kg should be dosed according to adult recommendations.Table 1. Pediatric CPS Dosing RecommendationsTotal Daily*Total Daily*Body WeightStarting DoseMaintenance Dose†[kg][mg/day][mg/day]25 to 60††5002,000*Administered in two divided doses.†Maintenance dose is based on 3,000 mg/day adult-equivalent dose†† Patients weighing more than 60 kg should be dosed according to adult recommendationsIn patients with refractory complex partial seizures, vigabatrin tablets should be withdrawn if a substantial clinical benefit is not observed within 3 months of initiating treatment. If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 3 months, treatment should be discontinued at that time [see Warnings and Precautions (5.1)].In a controlled study in pediatric patients with complex partial seizures, vigabatrin tablets were tapered by decreasing the daily dose by one third every week for three weeks [see Warnings and Precautions (5.6)].

2.4 Patients With Renal Impairment

  • Vigabatrin is primarily eliminated through the kidney.Adult and pediatric patients 10 years and olderMild renal impairment (CLcr greater than 50 to 80 mL/min): dose should be decreased by 25%Moderate renal impairment (CLcr greater than 30 to 50 mL/min): dose should be decreased by 50%Severe renal impairment (CLcr greater than 10 to 30 mL/min): dose should be decreased by 75%CLcr in mL/min may be estimated from serum creatinine (mg/dL) using the following formulas:Patients 10 to less than 12 years old: CLcr (mL/min/1.73 m2) = (K × Ht) / Scr                 height (Ht) in cm; serum creatinine (Scr) in mg/dL                      K (proportionality constant): Female Child (less than 12 years): K=0.55;                       Male Child (less than 12 years): K=0.70Adult and pediatric patients 12 years or older: CLcr (mL/min) = [140-age (years)] × weight (kg) / [72 × serum creatinine (mg/dL)] (×0.85 for female patients)The effect of dialysis on vigabatrin clearance has not been adequately studied [see Clinical Pharmacology (12.3) and Use in Specific Populations (8.6)].

3 Dosage Forms And Strengths

Vigabatrin tablets, USP are available for oral administration and are supplied as follows: 500 mg — Each white to off-white, film-coated, oval biconvex tablet functionally-scored on one side and debossed with A314 on the other side contains 500 mg of vigabatrin, USP.

4 Contraindications

None.

5.1 Permanent Vision Loss

Vigabatrin can cause permanent vision loss. Because of this risk and because, when it is effective, vigabatrin provides an observable symptomatic benefit; patient response and continued need for treatment should be periodically assessed.Based upon adult studies, 30 percent or more of patients can be affected with bilateral concentric visual field constriction ranging in severity from mild to severe. Severe cases may be characterized by tunnel vision to within 10 degrees of visual fixation, which can result in disability. In some cases, vigabatrin also can damage the central retina and may decrease visual acuity. Symptoms of vision loss from vigabatrin are unlikely to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function.Because assessing vision may be difficult in children, the frequency and extent of vision loss is poorly characterized in these patients. For this reason, the understanding of the risk is primarily based on the adult experience. The possibility that vision loss from vigabatrin may be more common, more severe, or have more severe functional consequences in children than in adults cannot be excluded.The onset of vision loss from vigabatrin is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.In patients with refractory complex partial seizures, vigabatrin should be withdrawn if a substantial clinical benefit is not observed within 3 months of initiating treatment. If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 3 months, treatment should be discontinued at that time [see Dosage and Administration (2.2) and Warnings and Precautions (5.6)].Vigabatrin should not be used in patients with, or at high risk of, other types of irreversible vision loss unless the benefits of treatment clearly outweigh the risks. The interaction of other types of irreversible vision damage with vision damage from vigabatrin has not been well-characterized, but is likely adverse.Vigabatrin should not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks.Monitoring of VisionMonitoring of vision by an ophthalmic professional with expertise in visual field interpretation and the ability to perform dilated indirect ophthalmoscopy of the retina is recommended [see Warnings and Precautions (5.2)]. For patients receiving vigabatrin, vision assessment is recommended at baseline (no later than 4 weeks after starting vigabatrin), at least every 3 months while on therapy, and about 3 to 6 months after the discontinuation of therapy. The diagnostic approach should be individualized for the patient and clinical situation.In adults and cooperative pediatric patients, perimetry is recommended, preferably by automated threshold visual field testing. Additional testing may also include electrophysiology (e.g., electroretinography [ERG]), retinal imaging (e.g., optical coherence tomography [OCT]), and/or other methods appropriate for the patient. In patients who cannot be tested, treatment may continue according to clinical judgment, with appropriate patient counseling. Because of variability, results from ophthalmic monitoring must be interpreted with caution, and repeat assessment is recommended if results are abnormal or uninterpretable. Repeat assessment in the first few weeks of treatment is recommended to establish if, and to what degree, reproducible results can be obtained, and to guide selection of appropriate ongoing monitoring for the patient.The onset and progression of vision loss from vigabatrin is unpredictable, and it may occur or worsen precipitously between assessments. Once detected, vision loss due to vigabatrin is not reversible. It is expected that even with frequent monitoring, some vigabatrin patients will develop severe vision loss. Consider drug discontinuation, balancing benefit and risk, if vision loss is documented. It is possible that vision loss can worsen despite discontinuation of vigabatrin.

5.2 Vigabatrin Rems Program

  • Vigabatrin tablets are available only through a restricted distribution program called the Vigabatrin REMS Program, because of the risk of permanent vision loss.Notable requirements of the Vigabatrin REMS Program include the following:Prescribers must be certified by enrolling in the program, agreeing to counsel patients on the risk of vision loss and the need for periodic monitoring of vision, and reporting any event suggestive of vision loss to Teva Pharmaceuticals USA, Inc.Patients must enroll in the program.Pharmacies must be certified and must only dispense to patients authorized to receive vigabatrin tablets.Further information is available at www.vigabatrinREMS.com or call 1-866-244-8175.

5.3 Magnetic Resonance Imaging (Mri) Abnormalities In Infants

Abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in some infants treated with vigabatrin for infantile spasms. In a retrospective epidemiologic study in infants with IS (N=205), the prevalence of these changes was 22% in vigabatrin treated patients versus 4% in patients treated with other therapies.In the study above, in post marketing experience, and in published literature reports, these changes generally resolved with discontinuation of treatment. In a few patients, the lesion resolved despite continued use. It has been reported that some infants exhibited coincident motor abnormalities, but no causal relationship has been established and the potential for long-term clinical sequelae has not been adequately studied.Neurotoxicity (brain histopathology and neurobehavioral abnormalities) was observed in rats exposed to vigabatrin during late gestation and the neonatal and juvenile periods of development, and brain histopathological changes were observed in dogs exposed to vigabatrin during the juvenile period of development. The relationship between these findings and the abnormal MRI findings in infants treated with vigabatrin for infantile spasms is unknown [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1)].The specific pattern of signal changes observed in IS patients was not observed in older pediatric and adult patients treated with vigabatrin for refractory CPS. In a blinded review of MRI images obtained in prospective clinical trials in patients with refractory CPS 3 years and older (N=656), no difference was observed in anatomic distribution or prevalence of MRI signal changes between vigabatrin treated and placebo treated patients.For adults treated with vigabatrin, routine MRI surveillance is unnecessary as there is no evidence that vigabatrin causes MRI changes in this population.

5.4 Neurotoxicity

Vacuolation, characterized by fluid accumulation and separation of the outer layers of myelin, has been observed in brain white matter tracts in adult and juvenile rats and adult mice, dogs, and possibly monkeys following administration of vigabatrin. This lesion, referred to as intramyelinic edema (IME), was seen in animals at doses within the human therapeutic range. A no-effect dose was not established in rodents or dogs. In the rat and dog, vacuolation was reversible following discontinuation of vigabatrin treatment, but, in the rat, pathologic changes consisting of swollen or degenerating axons, mineralization, and gliosis were seen in brain areas in which vacuolation had been previously observed. Vacuolation in adult animals was correlated with alterations in MRI and changes in visual and somatosensory evoked potentials (EP).Administration of vigabatrin to rats during the neonatal and juvenile periods of development produced vacuolar changes in the brain gray matter (including the thalamus, midbrain, deep cerebellar nuclei, substantia nigra, hippocampus, and forebrain) which are considered distinct from the IME observed in vigabatrin treated adult animals. Decreased myelination and evidence of oligodendrocyte injury were additional findings in the brains of vigabatrin-treated rats. An increase in apoptosis was seen in some brain regions following vigabatrin exposure during the early postnatal period. Long-term neurobehavioral abnormalities (convulsions, neuromotor impairment, learning deficits) were also observed following vigabatrin treatment of young rats. Administration of vigabatrin to juvenile dogs produced vacuolar changes in the brain gray matter (including the septal nuclei, hippocampus, hypothalamus, thalamus, cerebellum, and globus pallidus). Neurobehavioral effects of vigabatrin were not assessed in the juvenile dog. These effects in young animals occurred at doses lower than those producing neurotoxicity in adult animals and were associated with plasma vigabatrin levels substantially lower than those achieved clinically in infants and children [see Use in Specific Populations (8.1, 8.4)].In a published study, vigabatrin (200, 400 mg/kg/day) induced apoptotic neurodegeneration in the brain of young rats when administered by intraperitoneal injection on postnatal days 5 to 7.Administration of vigabatrin to female rats during pregnancy and lactation at doses below those used clinically resulted in hippocampal vacuolation and convulsions in the mature offspring.Abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in some infants treated for IS with vigabatrin. Studies of the effects of vigabatrin on MRI and EP in adult epilepsy patients have demonstrated no clear-cut abnormalities [see Warnings and Precautions (5.3)].

5.5 Suicidal Behavior And Ideation

Antiepileptic drugs (AEDs), including vigabatrin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive-therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug treated patients in the trials and none in placebo treated patients, but the number is too small to allow any conclusion about drug effect on suicide.The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 4 shows absolute and relative risk by indication for all evaluated AEDs.Table 4. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis IndicationPlacebo Patients with Events per 1,000 Patients  Drug Patients with Events per 1,000 Patients Relative Risk:Incidence of Drug Events in Drug Patients/Incidence in Placebo Patients Risk Difference: Additional Drug Patients with Events per 1,000 PatientsEpilepsy1.03.43.52.4Psychiatric5.78.51.52.9Other1.01.81.90.9Total2.44.31.81.9The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.Anyone considering prescribing vigabatrin or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

5.6 Withdrawal Of Antiepileptic Drugs (Aeds)

As with all AEDs, vigabatrin should be withdrawn gradually. However, if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered. Patients and caregivers should be told not to suddenly discontinue vigabatrin therapy.In controlled clinical studies in adults with complex partial seizures, vigabatrin was tapered by decreasing the daily dose 1,000 mg/day on a weekly basis until discontinued.In a controlled study in pediatric patients with complex partial seizures, vigabatrin was tapered by decreasing the daily dose by one third every week for three weeks.

5.7 Anemia

In North American controlled trials in adults, 6% of patients (16/280) receiving vigabatrin and 2% of patients (3/188) receiving placebo had adverse events of anemia and/or met criteria for potentially clinically important hematology changes involving hemoglobin, hematocrit, and/or RBC indices. Across U.S. controlled trials, there were mean decreases in hemoglobin of about 3% and 0% in vigabatrin and placebo treated patients, respectively, and a mean decrease in hematocrit of about 1% in vigabatrin treated patients compared to a mean gain of about 1% in patients treated with placebo.In controlled and open label epilepsy trials in adults and pediatric patients, 3 vigabatrin patients (0.06%, 3/4855) discontinued for anemia and 2 vigabatrin patients experienced unexplained declines in hemoglobin to below 8 g/dL and/or hematocrit below 24%.

5.8 Somnolence And Fatigue

Vigabatrin causes somnolence and fatigue. Patients should be advised not to drive a car or operate other complex machinery until they are familiar with the effects of vigabatrin on their ability to perform such activities.Pooled data from two vigabatrin controlled trials in adults demonstrated that 24% (54/222) of vigabatrin patients experienced somnolence compared to 10% (14/135) of placebo patients. In those same studies, 28% of vigabatrin patients experienced fatigue compared to 15% (20/135) of placebo patients. Almost 1% of vigabatrin patients discontinued from clinical trials for somnolence and almost 1% discontinued for fatigue.Pooled data from three vigabatrin controlled trials in pediatric patients demonstrated that 6% (10/165) of vigabatrin patients experienced somnolence compared to 5% (5/104) of placebo patients. In those same studies, 10% (17/165) of vigabatrin patients experienced fatigue compared to 7% (7/104) of placebo patients. No vigabatrin patients discontinued from clinical trials due to somnolence or fatigue.

5.9 Peripheral Neuropathy

Vigabatrin causes symptoms of peripheral neuropathy in adults. Pediatric clinical trials were not designed to assess symptoms of peripheral neuropathy, but observed incidence of symptoms based on pooled data from controlled pediatric studies appeared similar for pediatric patients on vigabatrin and placebo. In a pool of North American controlled and uncontrolled epilepsy studies, 4.2% (19/457) of vigabatrin patients developed signs and/or symptoms of peripheral neuropathy. In the subset of North American placebo-controlled epilepsy trials, 1.4% (4/280) of vigabatrin treated patients and no (0/188) placebo patients developed signs and/or symptoms of peripheral neuropathy. Initial manifestations of peripheral neuropathy in these trials included, in some combination, symptoms of numbness or tingling in the toes or feet, signs of reduced distal lower limb vibration or position sensation, or progressive loss of reflexes, starting at the ankles. Clinical studies in the development program were not designed to investigate peripheral neuropathy systematically and did not include nerve conduction studies, quantitative sensory testing, or skin or nerve biopsy. There is insufficient evidence to determine if development of these signs and symptoms was related to duration of vigabatrin treatment, cumulative dose, or if the findings of peripheral neuropathy were completely reversible upon discontinuation of vigabatrin.

5.10 Weight Gain

Vigabatrin causes weight gain in adult and pediatric patients.Data pooled from randomized controlled trials in adults found that 17% (77/443) of vigabatrin patients versus 8% (22/275) of placebo patients gained greater than or equal to 7% of baseline body weight. In these same trials, the mean weight change among vigabatrin patients was 3.5 kg compared to 1.6 kg for placebo patients.Data pooled from randomized controlled trials in pediatric patients with refractory complex partial seizures found that 47% (77/163) of vigabatrin patients versus 19% (19/102) of placebo patients gained greater than or equal to 7% of baseline body weight.In all epilepsy trials, 0.6% (31/4855) of vigabatrin patients discontinued for weight gain. The long term effects of vigabatrin related weight gain are not known. Weight gain was not related to the occurrence of edema.

5.11 Edema

Vigabatrin causes edema in adults. Pediatric clinical trials were not designed to assess edema, but observed incidence of edema based pooled data from controlled pediatric studies appeared similar for pediatric patients on vigabatrin and placebo.Pooled data from controlled trials demonstrated increased risk among vigabatrin patients compared to placebo patients for peripheral edema (vigabatrin 2%, placebo 1%), and edema (vigabatrin 1%, placebo 0%). In these studies, one vigabatrin and no placebo patients discontinued for an edema related AE. In adults, there was no apparent association between edema and cardiovascular adverse events such as hypertension or congestive heart failure. Edema was not associated with laboratory changes suggestive of deterioration in renal or hepatic function.

6 Adverse Reactions

  • The following serious and otherwise important adverse reactions are described elsewhere in labeling:Permanent Vision Loss [see BOXED WARNING and Warnings and Precautions (5.1)]Magnetic Resonance Imaging (MRI) Abnormalities in Infants [see Warnings and Precautions (5.3)]Neurotoxicity [see Warnings and Precautions (5.4)]Suicidal Behavior and Ideation [see Warnings and Precautions (5.5)]Withdrawal of Antiepileptic Drugs (AEDs) [see Warnings and Precautions (5.6)]Anemia [see Warnings and Precautions (5.7)]Somnolence and Fatigue [see Warnings and Precautions (5.8)]Peripheral Neuropathy [see Warnings and Precautions (5.9)]Weight Gain [see Warnings and Precautions (5.10)]Edema [see Warnings and Precautions (5.11)]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.In U.S. and primary non-U.S. clinical studies of 4,079 vigabatrin treated patients, the most common (greater than or equal to 5%) adverse reactions associated with the use of vigabatrin in combination with other AEDs were headache, somnolence, fatigue, dizziness, convulsion, nasopharyngitis, weight gain, upper respiratory tract infection, visual field defect, depression, tremor, nystagmus, nausea, diarrhea, memory impairment, insomnia, irritability, abnormal coordination, blurred vision, diplopia, vomiting, influenza, pyrexia, and rash.The adverse reactions most commonly associated with vigabatrin treatment discontinuation in greater than or equal to 1% of patients were convulsion and depression.Refractory Complex Partial SeizuresAdultsTable 5 lists the adverse reactions that occurred in greater than or equal to 2% and more than one patient per vigabatrin treated group and that occurred more frequently than in placebo patients from 2 U.S. add-on clinical studies of refractory CPS in adults.Table 5. Adverse Reactions in Pooled, Add-On Trials in Adults with Refractory Complex Partial SeizuresVigabatrin Dosage(mg/day)30006000PlaceboBody System[N=134][N=43][N=135]    Adverse Reaction%%%Ear Disorders    Tinnitus201    Vertigo 251Eye Disorders    Blurred vision13165    Diplopia7163    Asthenopia220    Eye pain050Gastrointestinal Disorders    Diarrhea10167    Nausea1028    Vomiting796    Constipation853    Upper abdominal pain551    Dyspepsia453    Stomach discomfort421    Abdominal pain321    Toothache252    Abdominal distension201General Disorders    Fatigue234016    Gait disturbance6127    Asthenia571    Edema peripheral571    Fever473    Chest pain151    Thirst200    Malaise050Infections    Nasopharyngitis14910    Upper respiratory tract infection796    Influenza574    Urinary tract infection450    Bronchitis051Injury    Contusion352    Joint sprain121    Muscle strain121    Wound secretion020Metabolism and Nutrition Disorders    Increased appetite151    Weight gain6143Musculoskeletal Disorders    Arthralgia1053    Back pain472    Pain in extremity624    Myalgia351    Muscle twitching191    Muscle spasms301Nervous System Disorders    Headache332631    Somnolence222613    Dizziness242617    Nystagmus13199    Tremor15168    Memory impairment7163    Abnormal coordination7162    Disturbance in attention901    Sensory disturbance472    Hyporeflexia451    Paraesthesia721    Lethargy472    Hyperreflexia423    Hypoaesthesia451    Sedation400    Status epilepticus250    Dysarthria221    Postictal state201    Sensory loss050Psychiatric Disorders    Irritability7237    Depression6143    Confusional state4141    Anxiety403    Depressed mood501    Abnormal thinking370    Abnormal behavior351    Expressive language disorder171    Nervousness252    Abnormal dreams151Reproductive System    Dysmenorrhea953    Erectile dysfunction050Respiratory and Thoracic Disorders    Pharyngolaryngeal pain7145    Cough2147    Pulmonary congestion051    Sinus headache621Skin and Subcutaneous Tissue Disorders   Rash454Pediatrics 10 to 16 years of ageTable 6 lists adverse reactions from controlled clinical studies of pediatric patients receiving vigabatrin or placebo as add-on therapy for refractory complex partial seizures. Adverse reactions that are listed occurred in at least 2% of vigabatrin treated patients and more frequently than placebo. The median vigabatrin dose was 49.4 mg/kg (range of 8.0 to 105.9 mg/kg).Table 6. Adverse Reactions in Pooled, Add-On Trials in Pediatric Patients 10 to 16 Years of Age with Refractory Complex Partial SeizuresAll VigabatrinPlaceboBody System[N=109][N=46]     Adverse Reaction%%Eye Disorders     Diplopia50     Blurred vision30Gastrointestinal Disorders     Diarrhea62     Upper abdominal pain30     Constipation32General Disorders     Fatigue94Infections and Infestations     Upper respiratory tract infection104     Influenza62     Otitis media62Investigations     Weight gain172Nervous System Disorders     Somnolence62     Tremor60     Nystagmus52    Psychomotor hyperactivity42Psychiatric Disorders     Abnormal behavior62     Aggression50     Disorientation40Reproduction and Breast Disorders    Dysmenorrhea30Skin and Subcutaneous Tissue Disorders    Acne30

6.2 Postmarketing Experience

The following adverse reactions have been reported during post approval use of vigabatrin worldwide. All adverse reactions that are not listed above as adverse reactions reported in clinical trials, that are not relatively common in the population and are not too vague to be useful are listed in this section. These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class.Birth Defects: Congenital cardiac defects, congenital external ear anomaly, congenital hemangioma, congenital hydronephrosis, congenital male genital malformation, congenital oral malformation, congenital vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, talipesEar Disorders: DeafnessEndocrine Disorders: Delayed pubertyGastrointestinal Disorders: Gastrointestinal hemorrhage, esophagitisGeneral Disorders: Developmental delay, facial edema, malignant hyperthermia, multi-organ failureHepatobiliary Disorders: CholestasisNervous System Disorders: Dystonia, encephalopathy, hypertonia, hypotonia, muscle spasticity, myoclonus, optic neuritis, dyskinesiaPsychiatric Disorders: Acute psychosis, apathy, delirium, hypomania, neonatal agitation, psychotic disorderRespiratory Disorders: Laryngeal edema, pulmonary embolism, respiratory failure, stridorSkin and Subcutaneous Tissue Disorders: Angioedema, maculo-papular rash, pruritus, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), alopecia

7.1 Antiepileptic Drugs

PhenytoinAlthough phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since vigabatrin may cause a moderate reduction in total phenytoin plasma levels [see Clinical Pharmacology (12.3)].ClonazepamVigabatrin may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions [see Clinical Pharmacology (12.3)].Other AEDsThere are no clinically significant pharmacokinetic interactions between vigabatrin and either phenobarbital or sodium valproate. Based on population pharmacokinetics, carbamazepine, clorazepate, primidone, and sodium valproate appear to have no effect on plasma concentrations of vigabatrin [see Clinical Pharmacology (12.3)].

7.2 Oral Contraceptives

Vigabatrin is unlikely to affect the efficacy of steroid oral contraceptives [see Clinical Pharmacology (12.3)].

7.3 Drug-Laboratory Test Interactions

Vigabatrin decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury.Vigabatrin may increase the amount of amino acids in the urine, possibly leading to a false positive test for certain rare genetic metabolic diseases (e.g., alpha aminoadipic aciduria).

8.1 Pregnancy

Pregnancy Category C.Vigabatrin produced developmental toxicity, including teratogenic and neurohistopathological effects, when administered to pregnant animals at clinically relevant doses. In addition, developmental neurotoxicity was observed in rats treated with vigabatrin during a period of postnatal development corresponding to the third trimester of human pregnancy. There are no adequate and well-controlled studies in pregnant women. Vigabatrin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Administration of vigabatrin (oral doses of 50 to 200 mg/kg) to pregnant rabbits throughout the period of organogenesis was associated with an increased incidence of malformations (cleft palate) and embryo-fetal death; these findings were observed in two separate studies. The no-effect dose for teratogenicity and embryolethality in rabbits (100 mg/kg) is approximately 1/2 the maximum recommended human dose (MRHD) of 3 g/day on a body surface area (mg/m2) basis. In rats, oral administration of vigabatrin (50, 100, or 150 mg/kg) throughout organogenesis resulted in decreased fetal body weights and increased incidences of fetal anatomic variations. The no-effect dose for embryo-fetal toxicity in rats (50 mg/kg) is approximately 1/5 the MRHD on a mg/m2 basis. Oral administration of vigabatrin (50, 100, 150 mg/kg) to rats from the latter part of pregnancy through weaning produced long-term neurohistopathological (hippocampal vacuolation) and neurobehavioral (convulsions) abnormalities in the offspring. A no-effect dose for developmental neurotoxicity in rats was not established; the low-effect dose (50 mg/kg) is approximately 1/5 the MRHD on a mg/m2 basis.In a published study, vigabatrin (300 or 450 mg/kg) was administered by intraperitoneal injection to a mutant mouse strain on a single day during organogenesis (day 7, 8, 9, 10, 11, or 12). An increase in malformations (including cleft palate) was observed at both doses.Oral administration of vigabatrin (5, 15, or 50 mg/kg) to young rats during the neonatal and juvenile periods of development (postnatal days 4 to 65) produced neurobehavioral (convulsions, neuromotor impairment, learning deficits) and neurohistopathological (brain vacuolation, decreased myelination, and retinal dysplasia) abnormalities in treated animals. The early postnatal period in rats is generally thought to correspond to late pregnancy in humans in terms of brain development. The no-effect dose for developmental neurotoxicity in juvenile rats (5 mg/kg) was associated with plasma vigabatrin exposures (AUC) less than 1/30 of those measured in pediatric patients receiving an oral dose of 50 mg/kg.Pregnancy RegistryTo provide information regarding the effects of in utero exposure to vigabatrin, physicians are advised to recommend that pregnant patients taking vigabatrin enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.

8.3 Nursing Mothers

Vigabatrin is excreted in human milk. Because of the potential for serious adverse reactions from vigabatrin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother [see Warnings and Precautions (5.3, 5.4)].

8.4 Pediatric Use

The safety and effectiveness of vigabatrin as adjunctive treatment of refractory complex partial seizures in pediatric patients aged 10 to 16 years of age have been established [see Clinical Studies (14.1)]. The dosing recommendation in this population varies according to age group and is weight based [see Dosage and Administration (2.2)]. Adverse reactions in this pediatric population are similar to those observed in the adult population [see Adverse Reactions (6.1)].The safety and effectiveness of vigabatrin have not been established in pediatric patients under 10 years of age with refractory complex partial seizures.Abnormal MRI signal changes were observed in infants [see Warnings and Precautions (5.3, 5.4)].Oral administration of vigabatrin (5, 15, or 50 mg/kg) to young rats during the neonatal and juvenile periods of development (postnatal days 4 to 65) produced neurobehavioral (convulsions, neuromotor impairment, learning deficits) and neurohistopathological (brain gray matter vacuolation, decreased myelination, and retinal dysplasia) abnormalities. The no-effect dose for developmental neurotoxicity in juvenile rats (the lowest dose tested) was associated with plasma vigabatrin exposures (AUC) substantially less than those measured in pediatric patients at recommended doses. In dogs, oral administration of vigabatrin (30 or 100 mg/kg) during selected periods of juvenile development (postnatal days 22 to 112) produced neurohistopathological abnormalities (brain gray matter vacuolation). Neurobehavioral effects of vigabatrin were not assessed in the juvenile dog. A no-effect dose for neurohistopathology was not established in juvenile dogs; the lowest effect dose (30 mg/kg) was associated with plasma vigabatrin exposures lower than those measured in pediatric patients at recommended doses [see Warnings and Precautions (5.4)].

8.5 Geriatric Use

Clinical studies of vigabatrin did not include sufficient numbers of patients aged 65 and over to determine whether they responded differently from younger patients.Vigabatrin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.Oral administration of a single dose of 1.5 g of vigabatrin to elderly (greater than or equal to 65 years) patients with reduced creatinine clearance (less than 50 mL/min) was associated with moderate to severe sedation and confusion in 4 of 5 patients, lasting up to 5 days. The renal clearance of vigabatrin was 36% lower in healthy elderly subjects (greater than or equal to 65 years) than in young healthy males. Adjustment of dose or frequency of administration should be considered. Such patients may respond to a lower maintenance dose [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

8.6 Renal Impairment

Dose adjustment, including initiating treatment with a lower dose, is necessary in pediatric patients 10 years of age and older and adults with mild (creatinine clearance greater than 50 to 80 mL/min), moderate (creatinine clearance greater than 30 to 50 mL/min) and severe (creatinine clearance greater than 10 to 30 mL/min) renal impairment [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].

9.1 Controlled Substance

Vigabatrin is not a controlled substance.

9.2 Abuse

Vigabatrin did not produce adverse events or overt behaviors associated with abuse when administered to humans or animals. It is not possible to predict the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of vigabatrin (e.g., incrementation of dose, drug-seeking behavior).

9.3 Dependence

Following chronic administration of vigabatrin to animals, there were no apparent withdrawal signs upon drug discontinuation. However, as with all AEDs, vigabatrin should be withdrawn gradually to minimize increased seizure frequency [see Warnings and Precautions (5.6)].

10.1 Signs, Symptoms, And Laboratory Findings Of Overdosage

Confirmed and/or suspected vigabatrin overdoses have been reported during clinical trials and in post marketing surveillance. No vigabatrin overdoses resulted in death. When reported, the vigabatrin dose ingested ranged from 3 g to 90 g, but most were between 7.5 g and 30 g. Nearly half the cases involved multiple drug ingestions including carbamazepine, barbiturates, benzodiazepines, lamotrigine, valproic acid, acetaminophen, and/or chlorpheniramine.Coma, unconsciousness, and/or drowsiness were described in the majority of cases of vigabatrin overdose. Other less commonly reported symptoms included vertigo, psychosis, apnea or respiratory depression, bradycardia, agitation, irritability, confusion, headache, hypotension, abnormal behavior, increased seizure activity, status epilepticus, and speech disorder. These symptoms resolved with supportive care.

10.2 Management Of Overdosage

There is no specific antidote for vigabatrin overdose. Standard measures to remove unabsorbed drug should be used, including elimination by emesis or gastric lavage. Supportive measures should be employed, including monitoring of vital signs and observation of the clinical status of the patient.In an in vitro study, activated charcoal did not significantly adsorb vigabatrin.The effectiveness of hemodialysis in the treatment of vigabatrin overdose is unknown. In isolated case reports in renal failure patients receiving therapeutic doses of vigabatrin, hemodialysis reduced vigabatrin plasma concentrations by 40% to 60%.

11 Description

Vigabatrin tablets, USP are an oral antiepileptic drug and are available as white film-coated 500 mg tablets.The chemical name of vigabatrin USP, a racemate consisting of two enantiomers, is (±) 4-amino-5-hexenoic acid. The molecular formula is C6H11NO2 and the molecular weight is 129.16. It has the following structural formula:Vigabatrin, USP is a white to off-white powder which is freely soluble in water, slightly soluble in methyl alcohol, very slightly soluble in ethyl alcohol and chloroform, and insoluble in toluene and hexane. The pH of a 1% aqueous solution is about 6.9. The n-octanol/water partition coefficient of vigabatrin, USP is about 0.011 (log P=-1.96) at physiologic pH. Vigabatrin, USP melts with decomposition in a 3-degree range within the temperature interval of 171°C to 176°C. The dissociation constants (pKa) of vigabatrin, USP are 4 and 9.7 at room temperature (25°C).Each vigabatrin tablet contains 500 mg of vigabatrin, USP. The inactive ingredients are hypromellose 2910, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polyethylene glycol 8000, polysorbate 80, povidone, sodium starch glycolate, and titanium dioxide.

12.1 Mechanism Of Action

The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system.No direct correlation between plasma concentration and efficacy has been established. The duration of drug effect is presumed to be dependent on the rate of enzyme re-synthesis rather than on the rate of elimination of the drug from the systemic circulation.

12.2 Pharmacodynamics

Effects on Electrocardiogram There is no indication of a QT/QTc prolonging effect of vigabatrin in single doses up to 6.0 g. In a randomized, placebo-controlled, crossover study, 58 healthy subjects were administered a single oral dose of vigabatrin (3 g and 6 g) and placebo. Peak concentrations for 6.0 g vigabatrin were approximately 2-fold higher than the peak concentrations following the 3.0 g single oral dose.

12.3 Pharmacokinetics

Vigabatrin displayed linear pharmacokinetics after administration of single doses ranging from 0.5 g to 4 g, and after administration of repeated doses of 0.5 g and 2.0 g twice daily. Bioequivalence has been established between the oral solution and tablet formulations. The following PK information (Tmax, half-life, and clearance) of vigabatrin was obtained from stand-alone PK studies and population PK analyses.AbsorptionFollowing oral administration, vigabatrin is essentially completely absorbed. The time to maximum concentration (Tmax) is approximately 1 hour for children (10 years to 16 years) and adults. There was little accumulation with multiple dosing in adult and pediatric patients. A food effect study involving administration of vigabatrin to healthy volunteers under fasting and fed conditions indicated that the Cmax was decreased by 33%, Tmax was increased to 2 hours, and AUC was unchanged under fed conditions.DistributionVigabatrin does not bind to plasma proteins. Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).Metabolism and EliminationVigabatrin is not significantly metabolized; it is eliminated primarily through renal excretion. The terminal half-life of vigabatrin is about 9.5 hours for children (10 years to 16 years), and 10.5 hours for adults. Following administration of [14]C-vigabatrin to healthy male volunteers, about 95% of total radioactivity was recovered in the urine over 72 hours with the parent drug representing about 80% of this. Vigabatrin induces CYP2C9, but does not induce other hepatic cytochrome P450 enzyme systems.Specific PopulationsGeriatricThe renal clearance of vigabatrin in healthy elderly patients (greater than or equal to 65 years of age) was 36% less than those in healthy younger patients. This finding is confirmed by an analysis of data from a controlled clinical trial [see Use in Specific Populations (8.5)].PediatricThe clearance of vigabatrin is  5.8 L/hr for children (10 years to 16 years) and 7 L/hr for adults.GenderNo gender differences were observed for the pharmacokinetic parameters of vigabatrin in patients.RaceNo specific study was conducted to investigate the effects of race on vigabatrin pharmacokinetics. A cross study comparison between 23 Caucasian and 7 Japanese patients who received 1, 2, and 4 g of vigabatrin indicated that the AUC, Cmax, and half-life were similar for the two populations. However, the mean renal clearance of Caucasians (5.2 L/hr) was about 25% higher than the Japanese (4.0 L/hr). Inter-subject variability in renal clearance was 20% in Caucasians and was 30% in Japanese.Renal ImpairmentMean AUC increased by 30% and the terminal half-life increased by 55% (8.1 hr vs 12.5 hr) in adult patients with mild renal impairment (CLcr from greater than 50 to 80 mL/min) in comparison to normal subjects.Mean AUC increased by two-fold and the terminal half-life increased by two-fold in adult patients with moderate renal impairment (CLcr from greater than 30 to 50 mL/min) in comparison to normal subjects.Mean AUC increased by 4.5-fold and the terminal half-life increased by 3.5-fold in adult patients with severe renal impairment (CLcr from greater than 10 to 30 mL/min) in comparison to normal subjects.Adult patients with renal impairmentDosage adjustment, including starting at a lower dose, is recommended for adult patients with any degree of renal impairment [see Use in Specific Populations (8.6) and Dosage and Administration (2.4)].Pediatric patients 10 years and older with renal impairmentAlthough information is unavailable on the effects of renal impairment on vigabatrin clearance in pediatric patients 10 years and older, dosing can be calculated based upon adult data and an established formula [see Use in Specific Populations (8.6) and Dosage and Administration (2.4)].Hepatic ImpairmentVigabatrin is not significantly metabolized. The pharmacokinetics of vigabatrin in patients with impaired liver function has not been studied.Drug InteractionsPhenytoinA 16% to 20% average reduction in total phenytoin plasma levels was reported in adult controlled clinical studies. In vitro drug metabolism studies indicate that decreased phenytoin concentrations upon addition of vigabatrin therapy are likely to be the result of induction of cytochrome P450 2C enzymes in some patients. Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated [see Drug Interactions (7.1)].ClonazepamIn a study of 12 healthy adult volunteers, clonazepam (0.5 mg) co-administration had no effect on vigabatrin (1.5 g twice daily) concentrations. Vigabatrin increases the mean Cmax of clonazepam by 30% and decreases the mean Tmax by 45% [see Drug Interactions (7.1)].Other AEDsWhen co-administered with vigabatrin, phenobarbital concentration (from phenobarbital or primidone) was reduced by an average of 8% to 16%, and sodium valproate plasma concentrations were reduced by an average of 8%. These reductions did not appear to be clinically relevant. Based on population pharmacokinetics, carbamazepine, clorazepate, primidone, and sodium valproate appear to have no effect on plasma concentrations of vigabatrin [see Drug Interactions (7.1)].AlcoholCo-administration of ethanol (0.6 g/kg) with vigabatrin (1.5 g twice daily) indicated that neither drug influences the pharmacokinetics of the other.Oral ContraceptivesIn a double-blind, placebo-controlled study using a combination oral contraceptive containing 30 mcg ethinyl estradiol and 150 mcg levonorgestrel, vigabatrin (3 g/day) did not interfere significantly with the cytochrome P450 isoenzyme (CYP3A)-mediated metabolism of the contraceptive tested. Based on this study, vigabatrin is unlikely to affect the efficacy of steroid oral contraceptives. Additionally, no significant difference in pharmacokinetic parameters (elimination half-life, AUC, Cmax, apparent oral clearance, time to peak, and apparent volume of distribution) of vigabatrin were found after treatment with ethinyl estradiol and levonorgestrel [see Drug Interactions (7.2)].

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

Vigabatrin showed no carcinogenic potential in mouse or rat when given in the diet at doses up to 150 mg/kg/day for 18 months (mouse) or at doses up to 150 mg/kg/day for 2 years (rat). These doses are less than the maximum recommended human dose (MRHD) for refractory complex partial seizures (3 g/day) on a mg/m2 basis.Vigabatrin was negative in in vitro (Ames, CHO/HGPRT mammalian cell forward gene mutation, chromosomal aberration in rat lymphocytes) and in in vivo (mouse bone marrow micronucleus) assays.No adverse effects on male or female fertility were observed in rats at oral doses up to 150 mg/kg/day (approximately 1/2 the MRHD of 3 g/day on a mg/m2 basis) for adults treated with refractory complex partial seizures.

14.1 Complex Partial Seizures

AdultsThe effectiveness of vigabatrin as adjunctive therapy in adult patients was established in two U.S. multicenter, double-blind, placebo-controlled, parallel-group clinical studies. A total of 357 adults (age 18 to 60 years) with complex partial seizures, with or without secondary generalization were enrolled (Studies 1 and 2). Patients were required to be on an adequate and stable dose of an anticonvulsant, and have a history of failure on an adequate regimen of carbamazepine or phenytoin. Patients had a history of about 8 seizures per month (median) for about 20 years (median) prior to entrance into the study. These studies were not capable by design of demonstrating direct superiority of vigabatrin over any other anticonvulsant added to a regimen to which the patient had not adequately responded. Further, in these studies, patients had previously been treated with a limited range of anticonvulsants.The primary measure of efficacy was the patient’s reduction in mean monthly frequency of complex partial seizures plus partial seizures secondarily generalized at end of study compared to baseline.Study 1Study 1 (N=174) was a randomized, double-blind, placebo-controlled, dose-response study consisting of an 8-week baseline period followed by an 18-week treatment period. Patients were randomized to receive placebo or 1, 3, or 6 g/day vigabatrin administered twice daily. During the first 6 weeks following randomization, the dose was titrated upward beginning with 1 g/day and increasing by 0.5 g/day on days 1 and 5 of each subsequent week in the 3 g/day and 6 g/day groups, until the assigned dose was reached.Results for the primary measure of effectiveness, reduction in monthly frequency of complex partial seizures, are shown in Table 8. The 3 g/day and 6 g/day dose groups were statistically significantly superior to placebo, but the 6 g/day dose was not superior to the 3 g/day dose.                                         Table 8. Median Monthly Frequency of Complex Partial Seizures+NBaselineEnd-studyPlacebo459.08.81 g/day vigabatrin458.57.73 g/day vigabatrin418.53.7*6 g/day vigabatrin438.54.5**p<0.05 compared to placebo+Including one patient with simple partial seizures with secondary generalization onlyFigure 1 presents the percentage of patients (X-axis) with a percent reduction in seizure frequency (responder rate) from baseline to the maintenance phase at least as great as that represented on the Y-axis. A positive value on the Y-axis indicates an improvement from baseline (i.e., a decrease in complex partial seizure frequency), while a negative value indicates a worsening from baseline (i.e., an increase in complex partial seizure frequency). Thus, in a display of this type, a curve for an effective treatment is shifted to the left of the curve for placebo. The proportion of patients achieving any particular level of reduction in complex partial seizure frequency was consistently higher for the vigabatrin 3 and 6 g/day groups compared to the placebo group. For example, 51% of patients randomized to vigabatrin 3 g/day and 53% of patients randomized to vigabatrin 6 g/day experienced a 50% or greater reduction in seizure frequency, compared to 9% of patients randomized to placebo. Patients with an increase in seizure frequency greater than 100% are represented on the Y-axis as equal to or greater than -100%.Figure 1. Percent Reduction from Baseline in Seizure FrequencyStudy 2Study 2 (N=183 randomized, 182 evaluated for efficacy) was a randomized, double-blind, placebo-controlled, parallel study consisting of an 8-week baseline period and a 16-week treatment period. During the first 4 weeks following randomization, the dose of vigabatrin was titrated upward beginning with 1 g/day and increased by 0.5 g/day on a weekly basis to the maintenance dose of 3 g/day.Results for the primary measure of effectiveness, reduction in monthly complex partial seizure frequency, are shown in Table 9. Vigabatrin 3 g/day was statistically significantly superior to placebo in reducing seizure frequency.Table 9. Median Monthly Frequency of Complex Partial SeizuresNBaselineEnd-studyPlacebo909.07.53 g/day vigabatrin928.35.5* *p<0.05 compared to placeboFigure 2 presents the percentage of patients (X-axis) with a percent reduction in seizure frequency (responder rate) from baseline to the maintenance phase at least as great as that represented on the Y-axis. A positive value on the Y-axis indicates an improvement from baseline (i.e., a decrease in complex partial seizure frequency), while a negative value indicates a worsening from baseline (i.e., an increase in complex partial seizure frequency). Thus, in a display of this type, a curve for an effective treatment is shifted to the left of the curve for placebo. The proportion of patients achieving any particular level of reduction in seizure frequency was consistently higher for the vigabatrin 3 g/day group compared to the placebo group. For example, 39% of patients randomized to vigabatrin (3 g/day) experienced a 50% or greater reduction in complex partial seizure frequency, compared to 21% of patients randomized to placebo. Patients with an increase in seizure frequency greater than 100% are represented on the Y-axis as equal to or greater than -100%.Figure 2. Percent Reduction from Baseline in Seizure FrequencyFor both studies, there was no difference in the effectiveness of vigabatrin between male and female patients. Analyses of age and race were not possible as nearly all patients were between the ages of 18 to 65 and Caucasian.Pediatric patients 10 to 16 years of ageVigabatrin was studied in three double-blind, placebo-controlled, parallel-group studies in 269 patients who received vigabatrin and 104 patients who received placebo. No individual study was considered adequately powered to determine efficacy in pediatric patients age 10 years and above. The data from all three pediatric studies were pooled and used in a pharmacometric bridging analysis using weight-normalized doses to establish efficacy and determine appropriate dosing. All three studies were randomized, double-blind, placebo-controlled, parallel-group, adjunctive-treatment studies in patients aged 3 to 16 years with uncontrolled complex partial seizures with or without secondary generalization. The study period included a 6 to 10 week baseline phase and a 14 to 17 week treatment phase (composed of a titration and maintenance period).The pharmacometric bridging approach consisted of defining a weight-normalized dose-response, and showing that a similar dose-response relationship exists between pediatric patients and adult patients when vigabatrin was given as adjunctive therapy for complex partial seizures. Dosing recommendations in pediatric patients 10 to 16 years of age were derived from simulations utilizing these pharmacometric dose-response analyses [see Dosage and Administration (2.2)].

16.1 How Supplied

Vigabatrin tablets, USP are available for oral administration and are supplied as follows: 500 mg — Each white to off-white, film-coated, oval biconvex tablet functionally-scored on one side and debossed with A314 on the other side contains 500 mg of vigabatrin, USP. Tablets are supplied in bottles of 100 (NDC 0591-3851-01).

16.2 Storage And Handling

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].Dispense in a tight, light-resistant container that is defined in the USP.

17 Patient Counseling Information

  • Advise patients and caregivers to read the FDA-approved patient labeling (Medication Guide).Permanent Vision LossInform patients and caregivers of the risk of permanent vision loss, particularly loss of peripheral vision, from vigabatrin tablets, and the need for monitoring vision [see Warnings and Precautions (5.1)].Monitoring of vision, including assessment of visual fields and visual acuity, is recommended at baseline (no later than 4 weeks after starting vigabatrin tablets), at least every 3 months while on therapy, and about 3 to 6 months after discontinuation of therapy. In patients for whom vision testing is not possible, treatment may continue without recommended testing according to clinical judgment with appropriate patient or caregiver counseling. Patients or caregivers should be informed that if baseline or subsequent vision is not normal, vigabatrin tablets should only be used if the benefits of vigabatrin tablet treatment clearly outweigh the risks of additional vision loss.Advise patients and caregivers that vision testing may be insensitive and may not detect vision loss before it is severe. Also advise patients and caregivers that if vision loss is documented, such loss is irreversible. Ensure that both of these points are understood by patients and caregivers.Patients and caregivers should be informed that if changes in vision are suspected, they should notify their physician immediately. Vigabatrin REMS ProgramVigabatrin tablets are available only through a restricted program called the Vigabatrin REMS Program [see Warnings and Precautions (5.2)]. Inform patients/caregivers of the following:Patients/caregivers must be enrolled in the program.Vigabatrin tablets are only available through pharmacies that are enrolled in the Vigabatrin REMS Program.Suicidal Thinking and BehaviorCounsel patients, their caregiver(s), and families that AEDs, including vigabatrin tablets, may increase the risk of suicidal thoughts and behavior. Also advise patients and caregivers of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts of self-harm. Behaviors of concern should be reported immediately to healthcare providers [see Warnings and Precautions (5.5)].Use in PregnancyInstruct patients to notify their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breast feeding or intend to breast feed during therapy [see Use in Specific Populations (8.1, 8.3)].Encourage patients to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/ [see Use in Specific Populations (8.1)].Withdrawal of Vigabatrin Tablet TherapyInstruct patients and caregivers not to suddenly discontinue vigabatrin tablet therapy without consulting with their healthcare provider. As with all AEDs, withdrawal should normally be gradual [see Warnings and Precautions (5.6)].Manufactured in India by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIAManufactured for: Teva Pharmaceuticals USA, Inc.North Wales, PA 19454Revised — August 2018

Medication Guide

  • Vigabatrin (vye ga' ba trin) Tablets, USPWhat is the most important information I should know about vigabatrin? Vigabatrin can cause serious side effects, including:Permanent vision lossRisk of suicidal thoughts or actions1. Permanent vision loss:Vigabatrin can damage the vision of anyone who takes it. People who take vigabatrin do not lose all of their vision, but some people can have severe loss particularly to their ability to see to the side when they look straight ahead (peripheral vision). With severe vision loss, you may only be able to see things straight in front of you (sometimes called “tunnel vision”). You may also have blurry vision. If this happens, it will not get better.Vision loss and use of vigabatrin in adults and children 10 years and older: Because of the risk of vision loss, vigabatrin is used to treat complex partial seizures (CPS) only in people who do not respond well enough to several other medicines. Tell your healthcare provider right away if you (or your child):might not be seeing as well as before starting vigabatrinstart to trip, bump into things, or are more clumsy than usualare surprised by people or things coming in front of you that seem to come out of nowhereThese changes can mean that you (or your child) have damage to your vision.It is recommended that your healthcare provider test your (or your child’s) vision (including peripheral vision) and visual acuity (ability to read an eye chart) before you (or your child) start vigabatrin or within 4 weeks after starting vigabatrin, and at least every 3 months after that until vigabatrin is stopped. It is also recommended that you (or your child) have a vision test about 3 to 6 months after vigabatrin is stopped.Some people are not able to complete testing of vision. Your healthcare provider will determine if you (or your child) can be tested. If you (or your child) cannot complete vision testing, your healthcare provider may continue prescribing vigabatrin, but your healthcare provider will not be able to watch for any vision loss you (or your child) may get.Even if your vision (or your child’s vision) seems fine, it is important that you get these regular vision tests because vision damage can happen before you (or your child) notice any changes.These vision tests cannot prevent the vision damage that can happen with vigabatrin, but they do allow the healthcare provider to decide if you (or your child) should stop vigabatrin if vision has gotten worse, which usually will lessen further damage.If you do not have these vision tests regularly, your healthcare provider may stop prescribing vigabatrin.If you drive and your vision is damaged by vigabatrin, driving might be more dangerous, or you may not be able to drive safely at all. Talk about this with your healthcare provider.All people who take vigabatrin:You are at risk for permanent vision loss with any amount of vigabatrin.Your risk of vision loss may be higher the more vigabatrin you take daily and the longer you take it.It is not possible for your healthcare provider to know when vision loss will happen. It could happen soon after starting vigabatrin or any time during treatment. It may even happen after treatment has stopped. Because vigabatrin might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. Vigabatrin can only be prescribed to people who are enrolled in this program. As part of the Vigabatrin REMS Program, it is recommended that your healthcare provider test your (or your child’s) vision from time to time (periodically) while you (or your child) are being treated with vigabatrin, and even after you (or your child) stop treatment. Your healthcare provider will explain the details of the Vigabatrin REMS Program to you. For more information, go to www.vigabatrinREMS.com or call 1-866-244-8175.2. Risk of suicidal thoughts or actions:Like other antiepileptic drugs, vigabatrin may cause suicidal thoughts or actions in a very small number of people, about 1 in 500 people taking it. Call a healthcare provider right away if you or your child have any of these symptoms, especially if they are new, worse, or worry you:  ○ thoughts about suicide or dying                                            ○ attempts to commit suicide  ○ new or worse depression                                                      ○ new or worse anxiety  ○ feeling agitated or restless                                                    ○ panic attacks  ○ trouble sleeping (insomnia)                                                  ○ new or worse irritability  ○ acting aggressive, being angry, or violent                            ○ acting on dangerous impulses  ○ an extreme increase in activity and talking (mania)             ○ other unusual changes in behavior or moodSuicidal thoughts or actions can be caused by things other than medicines. If you or your child have suicidal thoughts or actions, your healthcare provider may check for other causes.How can I watch for early symptoms of suicidal thoughts and actions?Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.Keep all follow-up visits with your healthcare provider as scheduled.Call your healthcare provider between visits as needed, especially if you are worried about symptoms.Do not stop vigabatrin without first talking to a healthcare provider.Stopping vigabatrin suddenly can cause serious problems. Stopping a seizure medicine suddenly can cause seizures that will not stop (status epilepticus) in people who are being treated for seizures.What is vigabatrin?Vigabatrin is a prescription medicine used along with other treatments to treat adults and children 10 years and older with complex partial seizures (CPS) if:The CPS does not respond well enough to several other treatments, andYou and your healthcare provider decide the possible benefit of taking vigabatrin is more important than the risk of vision loss.Vigabatrin should not be the first medicine used to treat CPS.What should I tell my healthcare provider before starting vigabatrin?If you or your child has CPS, before taking vigabatrin tell your healthcare provider if you or your child have or had:depression, mood problems or suicidal thoughts or behavioran allergic reaction to vigabatrin, such as hives, itching, or trouble breathingany vision problemsany kidney problemslow red blood cell counts (anemia)any nervous or mental illnesses, such as depression, thoughts of suicide, or attempts at suicideany other medical conditionsare breastfeeding or planning to breastfeed. Vigabatrin can pass into breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take vigabatrin.are pregnant or plan to become pregnant. It is not known if vigabatrin will harm your unborn baby. You and your healthcare provider will have to decide if you should take vigabatrin while you are pregnant. Pregnancy Registry:If you become pregnant while taking vigabatrin, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Vigabatrin and other medicines may affect each other causing side effects.How should I take vigabatrin?Vigabatrin comes as tablets.You or your child will receive vigabatrin from a specialty pharmacy.Take vigabatrin exactly as your healthcare provider tells you to. Vigabatrin is usually taken 2 times each day.Vigabatrin may be taken with or without food.Before starting to take vigabatrin, talk to your healthcare provider about what you or your child should do if a vigabatrin dose is missed.If you or your child are taking vigabatrin for CPS and the seizures do not improve enough within 3 months, your healthcare provider will stop prescribing vigabatrin.Do not stop taking vigabatrin suddenly. This can cause serious problems. Stopping vigabatrin or any seizure medicine suddenly can cause seizures that will not stop (status epilepticus) in people who are being treated for seizures. You should follow your healthcare provider’s instructions on how to stop taking vigabatrin.Tell your healthcare provider right away about any increase in seizures when vigabatrin treatment is being stopped. Before your child starts taking vigabatrin, speak to your child’s healthcare provider about what to do if your child misses a dose, vomits, spits up, or only takes part of the dose of vigabatrin.Do not stop taking vigabatrin without talking to your healthcare provider. If vigabatrin improves your (or your child’s) seizures, you and your healthcare provider should talk about whether the benefit of taking vigabatrin is more important than the risk of vision loss, and decide if you (or your child) will continue to take vigabatrin.What should I avoid while taking vigabatrin?Vigabatrin causes sleepiness and tiredness. Adults taking vigabatrin should not drive, operate machinery, or perform any hazardous task, unless you and your healthcare provider have decided that you can do these things safely.What are the possible side effects of vigabatrin? Vigabatrin can cause serious side effects, including:See “What is the most important information I should know about vigabatrin?”sleepiness and tiredness. See “What should I avoid while taking vigabatrin?”weight gain that happens without swellingThe following serious side effects happen in adults. It is not known if these side effects also happen in babies who take vigabatrin.low red blood cell counts (anemia)nerve problems. Symptoms of a nerve problem can include numbness and tingling in your toes or feet. It is not known if nerve problems will go away after you stop taking vigabatrin.swelling If you or your child has CPS, vigabatrin may make certain types of seizures worse. Tell your healthcare provider right away if your (or your child's) seizures get worse.The most common side effects of vigabatrin in adults include:  ○ problems walking or feeling uncoordinated           ○ feeling dizzy  ○ shaking (tremor)                                                     ○ joint pain  ○ memory problems and not thinking clearly            ○ eye problems: blurry vision, double vision and eye                                                                                        movements that you cannot controlThe most common side effects of vigabatrin in children 10 to 16 years of age include:  ○ weight gain                                                              ○ upper respiratory tract infection  ○ tiredness                                                                  ○ aggression  ○ Also expect side effects like those seen in adults Tell your healthcare provider if you or your child have any side effect that bothers you or that does not go away. These are not all the possible side effects of vigabatrin.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should I store vigabatrin?Store vigabatrin tablets at room temperature, between 68°F to 77°F (20°C to 25°C).Keep vigabatrin tablets in the container they come in. Keep vigabatrin and all medicines out of the reach of children.General information about the safe and effective use of vigabatrin.Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about vigabatrin that is written for health professionals. Do not use vigabatrin for a condition for which it was not prescribed. Do not give vigabatrin to other people, even if they have the same symptoms that you have. It may harm them.What are the ingredients in vigabatrin tablets? Active Ingredient: vigabatrin, USPInactive Ingredients: hypromellose 2910, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polyethylene glycol 8000, polysorbate 80, povidone, sodium starch glycolate and titanium dioxide.Manufactured in India by: Watson Pharma Private Limited, Verna, Salcette Goa 403 722 INDIAManufactured for: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454 For more information call Teva Pharmaceuticals USA, Inc. at 1-888-838-2872.This Medication Guide has been approved by the U.S. Food and Drug Administration.Revised - 8/2018

* Please review the disclaimer below.

Previous Code
0591-3817
Next Code
0591-3856